Eric Finzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric Finzi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Allan Harrington
Johns Hopkins School of Medicine Baltimore Maryland USA
1 shared publication- Marc Axel Wollmer
Asklepios Clinic North - Ochsenzoll, Medical Faculty, Semmelweis University
1 shared publication - Michelle Magid
Department of Psychiatry, Dell Medical School at the University of Texas at Austin , Austin, TX
1 shared publication Norman E. Rosenthal
Capital Clinical Research Associates, Rockville, MD 20852, USA; Georgetown Medical School, Washington, DC 20057, USA
1 shared publication- Tillmann H. C. Krueger
Medizinische Hochschule Hannover
1 shared publication
Latest Publications
- Open Access
Treatment of Depression with Botulinum Toxin
Injection of botulinum toxin (BoNT) into the glabellar region of the face is a novel therapeutic approach in the treatment of depression. This treatment method has several advantages, including few side effects and a long-lasting, depot-like effect. Here we review the clinical and experimental evidence for the antidepressant effect of BoNT injections as well as the theoretical background and possible mechanisms of action. Moreover, we provide practical instructions for the safe and effective application of BoNT in the treatment of depression. Finally, we describe the current status of the clinical development of BoNT as an antidepressant and give an outlook on its potential future role in the management of mental disorders.
Open AccessTreatment of Depression with Botulinum Toxin
Injection of botulinum toxin (BoNT) into the glabellar region of the face is a novel therapeutic approach in the treatment of depression. This treatment method has several advantages, including few side effects and a long-lasting, depot-like effect. Here we review the clinical and experimental evidence for the antidepressant effect of BoNT injections as well as the theoretical background and possible mechanisms of action. Moreover, we provide practical instructions for the safe and effective application of BoNT in the treatment of depression. Finally, we describe the current status of the clinical development of BoNT as an antidepressant and give an outlook on its potential future role in the management of mental disorders.
- Open Access
- 21 January 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (5) , 2588-2590
Zinc treatment of outpatient COVID‐19: A retrospective review of 28 consecutive patients
- 21 January 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (5) , 2588-2590
Open AccessZinc treatment of outpatient COVID‐19: A retrospective review of 28 consecutive patients
- Open Access
- 1 October 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 99, 307-309
Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients
- 1 October 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 99, 307-309
Open AccessTreatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients
- 1 May 2014
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 52, 1-6
Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial
- 1 May 2014
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 52, 1-6
Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial